ASSEMBLY BIOSCIENCES INC (ASMB)
Health Care · Clinical-stage antiviral therapeutics · NASDAQ
Assembly Biosciences develops next-generation antivirals targeting herpes and hepatitis viruses, with a portfolio advancing through clinical trials and now powered by a Gilead partnership licensing its genital herpes program.
What ASSEMBLY BIOSCIENCES INC does
Assembly Biosciences is a biotechnology company developing innovative therapeutics targeting serious viral diseases including recurrent genital herpes, hepatitis delta virus (HDV), hepatitis B virus (HBV), and transplant-related herpesviruses. The company is advancing multiple clinical-stage investigational therapies through partnerships and internal development, most notably through a 2025 collaboration with Gilead Sciences in which Gilead exercised an option to license Assembly's helicase-primase inhibitor program for recurrent genital herpes treatment.
Themes: Antiviral therapeutics, Herpes simplex virus (HSV) treatment, Viral helicase-primase inhibitors, Hepatitis B and D treatment, Clinical-stage drug development
Fundamentals
- Price$34.38 as of 2026-08-21 close
- Market cap$700M as of 2026-08-21
- 1-year return+29.0% 2025-08-21 close $26.65 → 2026-08-21 close $34.38
- P/En/a negative earnings
- Net margin-9.0% as of 2026-08-24
- ROE-4.2% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+121.1% as of 2026-08-24
- Beta1.12 as of 2026-08-24
- Last reported earnings2026-05-07 SEC EDGAR Form 8-K (Item 2.02)
How ASMB compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ASSEMBLY BIOSCIENCES INC looks technically
ASSEMBLY BIOSCIENCES INC (ASMB) is trading 17.2% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 64 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 31, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 70, neither overbought (above 70) nor oversold (below 30). It just made a new 20-day high, its first since 2025-12-22, pushing above its recent trading range.
Trend
9
| Distance from the 200-day | it is trading 17.2% above its 200-day average, the long-term trend line — a longer-term uptrend | +17.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $26.96 | $26.96 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $29.34 | $29.34 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 23 calendar days ago — the swings before that are what the structure reading is measured on | 23 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 24.5. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 64 trading days ago — a "death cross", a bearish long-term signal | 64 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 17.2% above | +17.2% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 31, with buyers in control | 31.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 70, neither overbought (above 70) nor oversold (below 30) | 69.9 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($25.18 to $35.62) — its "stochastic" reading is 88 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 88.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 13 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $39.70 | $39.70 |
|---|---|---|
| From the 52-week high | it is 13.4% below its 52-week high (its highest price of the past year) | -13.4% |
| Above the 52-week low | it is 69.9% above its 52-week low (its lowest price of the past year) | +70.0% |
| Below the 52-week high | it is 13.4% below its highest point of the past year | 13.4% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2025-12-22, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, its first since 2025-12-22, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $811.57 (set on 2018-03-13) | $811.57 |
| Given back of the 52-week move | over the past year its closes ranged ($20.55 to $38.50), and it has given back roughly a quarter of its rise from last year’s low — 23% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $26.83 to $27.41. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 22.9% |
| From the all-time high | it is 95.8% below its all-time high | -95.8% |
| Nearest price level | it is trading 5.6% above a support level at $32.45 — a price it turned at twice since 2025-10-29, most recently on 2026-05-14. Since 2024-08-21 it has 13 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -5.6% |
| All-time low | its lowest closing price on record is $7.72 (set on 2023-11-22) | $7.72 |
| Above the all-time low | it is 345.2% above its all-time low | +345.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months) | 99th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.76 between its high and its low — about 5.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.76 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $22.00 and $34.71 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $22.00 – $28.35 – $34.71 |
| Typical daily range (% of price) | its price moves about 5.1% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.1% |
| Stretch from the 200-day average | it is trading 2.9 daily ranges above its 200-day average price (17.2% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.9 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.71× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.0% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +1.0% |
|---|---|---|
| Open gap | it gapped 2.3% above the previous close 2 sessions ago and has not traded back through the level it left behind at 32.13 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.3% |
| Gap filled | a 2.3% gap up opened on 2026-08-07 has been "filled" 10 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 10 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 27.6 percentage points (the stock gained 29.9% while the market gained 2.3%) | +27.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 26.6 percentage points (the stock gained 29.7% while the market gained 3.1%) | +26.6% |
| vs market, 6 months | over the past 6 months this stock beat the market by 8.5 percentage points (the stock gained 19.6% while the market gained 11.1%) | +8.5% |
| vs market, 12 months | over the past 12 months this stock beat the market by 8.5 percentage points (the stock gained 29.0% while the market gained 20.5%) | +8.5% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 27% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thin, spanning 1.0% of the share price, which is taken to mean a barrier that gives way easily. | +26.7% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 23% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $27.97 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +22.9% |
|---|
Price levels it has turned at before
ASMB last closed at $34.38 on 2026-08-21. Since 2024-08-21 it has turned at 13 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $32.45 | Support | 5.6% below the last close | turned there twice · 2025-10-29 to 2026-05-14 |
| $31.70 | Support | 7.8% below the last close | turned there twice · 2025-12-23 to 2026-05-22 |
| $30.82 | Support | 10.3% below the last close | turned there three times · 2025-10-20 to 2026-04-10 |
| $38.91 | Resistance | 13.2% above the last close | turned there twice · 2025-12-09 to 2025-12-22 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $24.50.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · beating the market · At the top of its 14-day range (stochastic above 80) | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 4 analysts
- Mean price target$50.00 range $43.00 – $62.00; median $47.50
Analyst estimates, as of 2026-08-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ASMB
- Consensus EPS estimate-$0.505 next reporting period, as of 2026-08-17
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on the Gilead Sciences collaboration for the HPI program — financial success depends on Gilead's commitment and the ability to realize anticipated financial benefits from the partnership","Clinical development risk — safety and efficacy data from ongoing studies may not warrant further development of product candidates or may fail to differentiate them from competitors","Funding and cash runway — the company is currently unprofitable and must secure additional capital to continue research, clinical studies, and business operations"]
What changed in the latest 10-Q
AI-assisted comparison of ASMB's 10-Q filed 2026-05-07 against the prior one filed 2025-11-10.
Management's Discussion & Analysis (MD&A)
- Reworded:
- Reference year changed from 'December 31, 2024' to 'December 31, 2025' in consolidated financial statements reference (newer filing 2026-05-07)
- Form 10-K filing date changed from 'March 20, 2025' to 'March 19, 2026' (newer filing 2026-05-07)
- Annual Report designation changed from '2024 Annual Report' to '2025 Annual Report' (newer filing 2026-05-07)
- Notes:
- Both texts appear truncated at 'Part I.' - comparison limited to available content
Risk Factors
- Added:
- Newer filing specifies HPI candidates as 'two long-acting helicase-primase inhibitors (HPI)' with explicit naming: 'ABI-5366 (5366) and ABI-1179 (1179)'
- Newer filing identifies 6250 as 'ABI-6250 (6250)' and 4334 as 'ABI-4334 (4334)' in the Overview section
- Newer filing adds: 'In December 2025, pursuant to our collaboration with Gilead Sciences, Inc. (Gilead and the Gilead Collaboration), Gilead exercised its option to license our HPI program for the treatment of recurrent genital herpes, including our long-acting investigational candidates 1179 and 5366'
- Newer filing states '2025 was a pivotal year for us' with data readouts and ABI-7272 nomination into regulatory-enabling studies
- Newer filing provides 2026 progress updates: '5366 and 1179 – All participants in the Phase 1a/b studies have completed dosing and follow up'
- Newer filing states for 6250: 'Chronic toxicology studies have been completed, establishing support for anticipated Phase 2 doses. Preparation for Phase 2 clinical studies is on-going, with initiation expected in the fourth quarter of 2026'
- Newer filing states for 4334: 'Initiated process to identify potential partners was initiated in the first quarter; we do not plan to advance 4334 further without a partner'
- Newer filing provides specific data: '94% reduction compared to placebo (p<0.01) over the 29-day eval' for 5366 Phase 1b HSV-2 shedding rate
- Removed:
- Older filing mentions office location: 'We currently have corporate and administrative offices and research laboratory space in South San Francisco, California' — removed in newer filing
- Older filing states 'we are developing a second novel, potent, long-acting HPI for genital herpes, 1179, which was exclusively in-licensed to us as part of our collaboration with Gilead, and also has demonstrated low nanomolar potency in vitro against both HSV-1 and HSV-2 clinical isolates and a favorable nonclinical safety profile in the FDA's GLP toxicology studies' — substantially modified in newer filing
- Older filing contains narrative about 7423/7272 transition: 'in December 2024, we identified a development candidate, ABI-7423 (7423)...in October 2025, we transitioned our discovery and development from 7423 to its parent molecule, ABI-7272 (7272)' — removed from newer filing's overview section
- Older filing includes market size language: 'over eight million people have been diagnosed with genital herpes, and it is estimated that there are over 60 million people living with HSV-2 infection' — removed in newer filing
- Older filing states 'we discovered and are developing' and includes details about 1179's in-licensing from Gilead — modified in newer filing to reflect Gilead's option exercise
- Reworded:
- Older: 'herpes simplex virus (HSV)' → Newer: specifies 'herpes simplex virus type 1 (HSV-1) or herpes simplex virus type 2 (HSV-2)' in Overview
- Older: 'genital lesions that can lead to increased transmission and debilitate patients' → Newer: 'debilitate individuals' (changed 'patients' to 'individuals')
- Older: 'are essential for HSV DNA replication' → Newer: 'are essential for viral DNA replication' (changed 'HSV' to 'viral')
- Older: 'Most people with initial symptomatic genital herpes who are infected with HSV-2 have frequent recurrences, generally between three and 15 per year. This includes an estimated population of over four million people...' → Newer: 'impacting over four million people...' (restructured and removed market size data)
- Older: describes program as 'we are developing' → Newer: reflects transition to Gilead with 'following completion of the Phase 1a/b studies of 5366 and 1179, which we are managing until they are complete'
- Notes:
- Text appears truncated at end of both sections; full comparison limited to available text
- Older filing text in HPI description section appears split across page boundary; comparison based on available content
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days.
- Last 90 days0 buys · 1 sell ($674) — 1 selling insider
- Last 180 days0 buys · 1 sell ($674) — 1 selling insider
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-17. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ASMB's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding ASMB as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 300,520
- Reported value $8,339,431
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
ASMB had 2,335,806 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
ASMB had 11.5% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 15.82 days to cover at the same settlement.
- Reported short interest (shares) 2,335,806
- Short interest (% of shares outstanding) 11.5%
- Prior settlement (shares) 2,312,058
- Reported change 1.03%
- Days to cover (reported) 15.82
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Gilead Sciences (GILD)
- Merck (MRK)
- Vertex Pharmaceuticals (VERX)
- Intercept Pharmaceuticals (ICPT)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ASMB vs…
ASSEMBLY BIOSCIENCES INC is found in…
Frequently asked questions
What does ASSEMBLY BIOSCIENCES INC (ASMB) do?
Assembly Biosciences is a biotechnology company developing innovative therapeutics targeting serious viral diseases including recurrent genital herpes, hepatitis delta virus (HDV), hepatitis B virus (HBV), and transplant-related herpesviruses. The company is advancing multiple clinical-stage investigational therapies through partnerships and internal development, most notably through a 2025 collaboration with Gilead Sciences in which Gilead exercised an option to license Assembly's…
What sector is ASSEMBLY BIOSCIENCES INC (ASMB) in?
ASSEMBLY BIOSCIENCES INC (ASMB) is classified in the Health Care sector. Its industry is Clinical-stage antiviral therapeutics. It trades on NASDAQ.
Who are ASSEMBLY BIOSCIENCES INC's (ASMB) competitors?
Notable peers of ASSEMBLY BIOSCIENCES INC (ASMB) include Gilead Sciences, Merck, Vertex Pharmaceuticals and Intercept Pharmaceuticals. This peer set is informational only — not financial advice.
Is ASSEMBLY BIOSCIENCES INC (ASMB) overbought or oversold right now?
ASSEMBLY BIOSCIENCES INC (ASMB) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 70, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ASMB come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.